Atherosclerotic Cardiovascular Disease – Special Topic – Special Topics: Physician Insights on Current Treatment Practices and Emerging Therapies for ASCVD (US)
Atherosclerotic cardiovascular disease (ASCVD) is caused by plaque buildup in arterial walls. Clinical / established ASCVD consists of acute coronary syndromes, a history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, carotid stenosis ≥ 50%, or symptomatic peripheral arterial disease—all of atherosclerotic origin. Patients with established ASCVD have a high risk of subsequent CVD events, including MI, stroke, and death. Statins are the mainstay of treatment for established clinical ASCVD. However, statins alone might not be enough to achieve target LDL-C lowering goals in ASCVD patients, and the addition of non-statin treatment is recommended. Even after the availability of multiple approved drugs, unmet need in ASCVD patients remains high; it is one of the top disease conditions contributing to overall mortality. Multiple non-statin drugs are in clinical development with different MOAs (e.g., PCSK9 inhibitors, CETP inhibitors, apolipoprotein inhibitors, IL-6 inhibitors). Increasing prevalence, combined with substantial unmet needs, makes the treatment of ASCVD a high-growth market opportunity. This report covers the current treatment practices for clinical / established ASCVD, the change in medical practice following the approval of additional non-statin drugs (e.g., Leqvio, Nexletol, Nexlizet), cardiologists’ awareness of upcoming drugs (e.g., lerodalcibep, olezarsen, olpasiran, MEDI6570, pelacarsen, ziltivekimab), and insights into physicians’ preference for various drug attributes.
Questions answered
- What proportion of clinical / established ASCVD patients fail to achieve LDL-C lowering targets with statin monotherapy and require non-statin drugs to achieve recommended LDL-C goals?
- Which are the most preferred statin + non-statin drug combinations?
- Will the newly approved PSCK9 siRNA drug (Leqvio) displace PCSK9 antibodies (Repatha, Praluent) in ASCVD patients? Why?
- What is the level of awareness among physicians about new targets and key emerging drug therapies being developed for the treatment of clinical / established ASCVD?
- What factors are expected to drive the adoption of emerging drugs?
Geography: United States.
Primary research: Survey of 100 U.S. cardiologists.
Key drugs covered: Leqvio, lerodalcibep, olezarsen, olpasiran, MEDI6570, pelacarsen, Praluent, Nexletol, Nexlizet, Repatha, Vascepa, ziltivekimab.
Key companies covered: Amgen, Amarin, AstraZeneca, Esperion, Ionis, LIB Therapeutics, NewAmsterdam, Novartis, Novo Nordisk, Regeneron.
Product description
This Special Topics report provides indication-specific market intelligence with keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
